10-Q: AptarGroup Reports 2% Sales Increase in Q3 2024, Driven by Pharma Growth

Sentiment:

Quarterly Report 25 October 2024 10:03 AM

AptarGroup's Q3 2024 results show a 2% increase in net sales, primarily driven by strong performance in the Pharma segment, while also announcing a new $500 million share repurchase program.

Better than expectedThe company's net income and operating income increased compared to the same period last year.The company's Adjusted EBITDA margin improved year-over-year.The company's free cash flow increased significantly compared to the same period last year.

Summary

AptarGroup's net sales for the third quarter of 2024 reached $909.3 million, a 2% increase compared to the same period in 2023.
Core sales, excluding acquisitions and currency fluctuations, also grew by 2% in Q3 2024.
The company's operating income for Q3 2024 was $138.3 million, up from $119.3 million in Q3 2023.
Net income attributable to AptarGroup, Inc. was $100.0 million for the third quarter of 2024, compared to $84.3 million in the same period last year.
For the first nine months of 2024, net sales increased by 3% to $2.73 billion, with core sales also up by 3%.
Operating income for the first nine months of 2024 was $376.4 million, compared to $319.8 million in the same period of 2023.
Net income attributable to AptarGroup, Inc. for the first nine months of 2024 was $273.6 million, compared to $222.1 million for the same period in the prior year.
The company's effective tax rate for the three months ended September 30, 2024 was 23.8%, and 22.7% for the nine months ended September 30, 2024.
AptarGroup announced a new share repurchase authorization of up to $500 million, replacing the previous $350 million authorization.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong performance in the Pharma segment and improved profitability, but also acknowledges challenges in other areas and potential risks. The new share repurchase program is a positive signal.

Positives

The Pharma segment demonstrated strong growth, with a 20% increase in core sales for prescription drug products in Q3 2024.
The company's cost of sales as a percentage of net sales decreased to 61.4% in Q3 2024, compared to 63.5% in Q3 2023.
AptarGroup's operating income increased by approximately $19.0 million in Q3 2024 compared to the same period last year.
The company's free cash flow increased significantly to $254.8 million for the first nine months of 2024.
AptarGroup successfully refinanced debt, repaying over $370 million of private placement debt and initiating new term loan and revolving credit facility borrowings.
The company's net debt to net capital ratio improved to 22.7% at September 30, 2024, indicating reduced leverage.

Negatives

The Beauty segment experienced a 7% decrease in reported net sales and a 6% decrease in core sales in Q3 2024.
Tooling sales were lower in both the Beauty and Closures segments, negatively impacting overall sales.
The company incurred higher compensation costs, including accruals related to short-term incentive compensation and certain equity compensation programs.
Interest expense increased by $2.3 million in Q3 2024 due to higher rates on current term loan and revolving credit facility borrowings.
The company's Corporate & Other Adjusted EBITDA increased to $15.4 million of expense in Q3 2024, compared to $11.7 million of expense in Q3 2023.

Risks

Geopolitical conflicts, including the invasion of Ukraine and events in the Middle East, could impact demand and supply chains.
The availability of raw materials and components, particularly from sole-sourced suppliers, poses a risk.
Economic conditions, including inflation and potential deflation, could affect demand and profitability.
Cybersecurity threats could impact the company's systems and reporting.
Fluctuations in foreign currency exchange rates could impact financial results.
Changes in tax laws and rates could affect the company's effective tax rate and cash flow.
The company faces competition and risks related to intellectual property rights.
The company's ability to meet future cash flow estimates to support goodwill impairment testing is a risk.

Future Outlook

AptarGroup expects earnings per share for the fourth quarter of 2024, excluding restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.22 to $1.30, based on an effective tax rate range of 20% to 22%.

Management Comments

Management believes the company is in a strong financial position to meet business requirements.
Management is focused on leveraging the fixed cost base through growth and cost reduction measures.
Management is monitoring the impact of macroeconomic conditions and has the ability to restrict capital expenditures and share repurchases if needed.

Industry Context

AptarGroup's performance reflects the broader trends in the packaging and dispensing solutions industry, with a focus on growth in the pharmaceutical sector and challenges in the beauty market. The company's strategic focus on innovation and cost management aligns with industry best practices.

Comparison to Industry Standards

AptarGroup's 2% sales growth in Q3 2024 is comparable to other companies in the packaging industry, which have seen moderate growth due to economic conditions.
The company's Adjusted EBITDA margin of 22.9% is competitive with industry benchmarks, indicating effective cost management.
The strong performance of the Pharma segment aligns with the increasing demand for drug delivery systems and healthcare packaging solutions.
The challenges in the Beauty segment reflect the broader market trends of fluctuating consumer demand and competitive pressures.
AptarGroup's focus on sustainability and innovation is consistent with the industry's move towards environmentally friendly and technologically advanced solutions.
Compared to competitors like Berry Global and Amcor, AptarGroup's focus on dispensing solutions provides a unique market position.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Executive Vice President, Chief Financial Officer	Robert W. Kuhn	TBD	December 31, 2024	Robert Kuhn will transition to a non-executive advisor role.
Chief Accounting Officer	Robert W. Kuhn	TBD	August 1, 2024	Robert Kuhn will transition to a non-executive advisor role.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
By-Laws Amendment	The Board of Directors adopted amendments to the Amended and Restated By-Laws, updating procedural mechanics for stockholder nominations and proposals, and adding an interview requirement for all director nominees.	October 23, 2024	The amendments align the by-laws with recent developments in Delaware law and enhance corporate governance practices.

Legal Proceedings

The company is subject to a number of lawsuits and claims in the normal course of business.
The company is defending its position with respect to custom duties assessments worth approximately $12 million in principal and $14 million to $15 million for interest and penalties.

Related Party Transactions

Aptar had purchases of $8.7 million from BTY for the nine months ended September 30, 2024.

Stakeholder Impact

Shareholders will benefit from the new share repurchase program and the company's improved financial performance.
Employees may be impacted by restructuring initiatives and changes in compensation programs.
Customers will benefit from the company's focus on innovation and quality.
Suppliers may be affected by changes in the company's supply chain and procurement strategies.

Next Steps

The company will continue to focus on growth in the Pharma segment and address challenges in the Beauty segment.
AptarGroup will continue to implement cost management initiatives and improve operational performance.
The company will execute its new $500 million share repurchase program.
AptarGroup will monitor macroeconomic conditions and adjust its strategies as needed.

Key Dates

Date	Description
January 1, 2020	Aptar acquired 49% of the equity interests in BTY.
April 1, 2020	Aptar invested $5.0 million to acquire 30% of the equity interests in Sonmol.
March 1, 2023	Aptar completed the acquisition of iD SCENT and 80% of Gulf Closures.
August 1, 2023	Aptar paid the remaining $5.2 million purchase price in relation to the 2021 Hengyu acquisition.
February 26, 2024	Aptar repaid in full the $100 million 3.49% Senior Unsecured Notes due in February 2024.
July 2, 2024	Aptar entered into a new amended and restated revolving credit facility agreement and a term loan agreement.
July 19, 2024	Aptar repaid in full the 200 million 1.17% Senior Unsecured Notes due in July 2024.
September 5, 2024	Aptar repaid in full the $50 million 3.4% Senior Unsecured Notes due in September 2024.
September 30, 2024	End of the reporting period for the quarterly report.
October 10, 2024	Aptar announced a new share repurchase authorization of up to $500 million and declared a quarterly cash dividend.
October 22, 2024	Aptar acquired 40% of the equity interests in Goldrain.
October 23, 2024	The Board of Directors adopted amendments to the Company's Amended and Restated By-Laws.
October 25, 2024	Date of filing of the quarterly report on Form 10-Q.
November 14, 2024	Date of payment of the quarterly cash dividend.
December 31, 2024	Robert Kuhn will cease to be the Executive Vice President, Chief Financial Officer.
January 1, 2025	Robert Kuhn will become a non-executive employee of the Company.
January 3, 2025	Robert Kuhn will become a non-employee advisor.
December 31, 2025	End of the Advisory Period for Robert Kuhn.

Keywords

AptarGroup, Pharma, Beauty, Closures, Net Sales, Operating Income, Adjusted EBITDA, Share Repurchase, Financial Results, Quarterly Report

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.